TW202313588A - 檢測點激酶１（ｃｈｋ１）抑制劑及其用途 - Google Patents
檢測點激酶１（ｃｈｋ１）抑制劑及其用途 Download PDFInfo
- Publication number
- TW202313588A TW202313588A TW111119737A TW111119737A TW202313588A TW 202313588 A TW202313588 A TW 202313588A TW 111119737 A TW111119737 A TW 111119737A TW 111119737 A TW111119737 A TW 111119737A TW 202313588 A TW202313588 A TW 202313588A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- tautomer
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| US63/193,990 | 2021-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202313588A true TW202313588A (zh) | 2023-04-01 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111119737A TW202313588A (zh) | 2021-05-27 | 2022-05-26 | 檢測點激酶１（ｃｈｋ１）抑制劑及其用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (enExample) |
| EP (1) | EP4347582A4 (enExample) |
| JP (1) | JP2024520481A (enExample) |
| KR (1) | KR20240021188A (enExample) |
| CN (1) | CN117715905A (enExample) |
| AU (1) | AU2022282384A1 (enExample) |
| BR (1) | BR112023024571A2 (enExample) |
| CA (1) | CA3219348A1 (enExample) |
| IL (1) | IL308759A (enExample) |
| MX (1) | MX2023014028A (enExample) |
| TW (1) | TW202313588A (enExample) |
| WO (1) | WO2022251502A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196614A4 (en) | 2020-08-12 | 2024-12-18 | Boundless Bio, Inc. | COMPOSITIONS OF REPLICATION STRESS SIGNAL PATHWAYS AND METHODS FOR TREATING CANCER |
| MX2023006364A (es) | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| JP2024520481A (ja) | 2021-05-27 | 2024-05-24 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
| EP4455134A4 (en) * | 2021-12-24 | 2025-10-08 | Sumitomo Pharma Co Ltd | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON |
| IL317138A (en) * | 2022-05-24 | 2025-01-01 | Boundless Bio Inc | Pyridine checkpoint kinase 1 (CHK1) inhibitors and their uses |
| WO2023226658A1 (en) * | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| WO2024196923A1 (en) * | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
| WO2025030049A1 (en) * | 2023-08-02 | 2025-02-06 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| NZ523656A (en) * | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN108601781B (zh) * | 2016-02-04 | 2019-11-22 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
| CN114728949B (zh) * | 2019-08-01 | 2024-11-12 | 曙方医药 | 作为激酶抑制剂的杂环化合物及其用途 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| MX2023000150A (es) * | 2020-06-19 | 2023-03-22 | Anaxis Pharma Pty Ltd | Compuesto de sulfonamida. |
| EP4196614A4 (en) | 2020-08-12 | 2024-12-18 | Boundless Bio, Inc. | COMPOSITIONS OF REPLICATION STRESS SIGNAL PATHWAYS AND METHODS FOR TREATING CANCER |
| JP2023547396A (ja) | 2020-10-23 | 2023-11-10 | セルジーン コーポレーション | 蠕虫感染及び疾患の処置のための複素環式化合物及びその使用 |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| JP2024520481A (ja) | 2021-05-27 | 2024-05-24 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
| EP4455134A4 (en) | 2021-12-24 | 2025-10-08 | Sumitomo Pharma Co Ltd | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON |
| IL317138A (en) | 2022-05-24 | 2025-01-01 | Boundless Bio Inc | Pyridine checkpoint kinase 1 (CHK1) inhibitors and their uses |
| WO2023226658A1 (en) | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| CN119403571A (zh) | 2022-05-27 | 2025-02-07 | 住友制药株式会社 | 对免疫检查点抑制剂示出治疗抗性的癌症的治疗药 |
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| WO2024196923A1 (en) | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
-
2022
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en active Pending
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12527790B2 (en) | 2026-01-20 |
| MX2023014028A (es) | 2023-12-12 |
| BR112023024571A2 (pt) | 2024-02-06 |
| CN117715905A (zh) | 2024-03-15 |
| CA3219348A1 (en) | 2022-12-01 |
| KR20240021188A (ko) | 2024-02-16 |
| US11707462B2 (en) | 2023-07-25 |
| JP2024520481A (ja) | 2024-05-24 |
| WO2022251502A1 (en) | 2022-12-01 |
| EP4347582A1 (en) | 2024-04-10 |
| US20230310423A1 (en) | 2023-10-05 |
| IL308759A (en) | 2024-01-01 |
| EP4347582A4 (en) | 2025-05-07 |
| US20230026313A1 (en) | 2023-01-26 |
| AU2022282384A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11707462B2 (en) | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | |
| WO2023230477A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| WO2024118564A1 (en) | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| TWI762505B (zh) | 細胞代謝過程之抑制劑 | |
| EP3902803B1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
| CN116723843A (zh) | 用于治疗和/或预防癌症的sos1抑制剂的药物组合 | |
| TW202039489A (zh) | Mat2a之雜雙環抑制劑及用於治療癌症之使用方法 | |
| CN107922431A (zh) | Hpk1抑制剂及其使用方法 | |
| WO2013170770A1 (zh) | 具有抗肿瘤活性的乙炔衍生物 | |
| EA021421B1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений | |
| CN118434417A (zh) | 环状磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途 | |
| US20240158383A1 (en) | Ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| EP4402134A1 (en) | Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| WO2024118596A1 (en) | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof | |
| US20260138968A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| EA051928B1 (ru) | Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение | |
| TWI423974B (zh) | 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用 | |
| CN120187718A (zh) | 环状磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途 | |
| TW201305153A (zh) | 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用 | |
| HK1255833B (en) | Hpk1 inhibitors and methods of using same |